PTCT Stock Cash Flow Statements

PTC Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

PTC Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30

cash flows from operating activities
net income	-64,849,000	866,562,000	-65,886,000	-106,654,000	-99,179,000	-91,576,000	-155,792,000	-132,970,000	-198,883,000	-138,959,000	-170,889,000	-109,315,000	-152,087,000	-126,726,000	-143,265,000	-133,624,000	-118,370,000	-128,642,000	-74,354,000	-69,692,000	-181,427,000	-112,687,000	-77,677,000	-59,997,000	-41,789,000	-72,113,000	-48,330,000	-50,969,000	-9,519,000	-19,263,000	1,270,000	-33,738,000	-17,475,000	-29,057,000	-26,796,000	-35,167,000	-38,914,000	-41,233,000	-43,223,000	-38,361,000	-37,915,000	-27,282,000	-25,104,000	-14,098,000	-4,416,499
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	7,583,000	7,221,000	6,764,000	6,486,000	7,018,000	55,395,000	80,705,000	62,055,000	51,005,000	42,825,000	38,865,000	34,477,000	29,180,000	26,314,000	18,811,000	16,750,000	14,986,000	13,587,000	12,402,000	11,643,000	10,210,000	9,235,000	9,277,000	8,143,000	7,701,000	7,059,000	6,771,000	7,073,000	6,221,000	6,022,000	5,939,000	10,295,000
non-cash operating lease expense	1,844,000	1,790,000	1,480,000	1,800,000	2,680,000	1,792,000	1,671,000	2,482,000	2,732,000	2,942,000	2,379,000	3,210,000	2,387,000	1,908,000	1,870,000	1,850,000	1,847,000	1,819,000	1,789,000	1,894,000
non-cash royalty revenue related to sale of future royalties	-52,125,000	-32,974,000	-52,630,000	-55,528,000	-48,121,000	-25,228,000	-42,861,000	-21,540,000	-15,822,000	-13,237,000	-17,121,000	-14,135,000	-9,369,000	-8,113,000	-9,143,000	-5,636,000	-5,823,000	-2,858,000
non-cash interest expense on liability related to sale of future royalties	49,668,000	49,661,000	52,355,000	52,699,000	52,276,000	50,064,000	48,759,000	18,278,000	18,851,000	18,902,000	16,861,000	17,953,000	18,951,000	18,874,000	19,928,000	19,672,000	20,003,000	18,080,000
change in valuation of contingent consideration	0	-800,000	-10,175,000	700,000	5,100,000	-100,000	-2,700,000	1,500,000
tangible asset impairment			2,609,000	1,318,000
loss on sale of fixed assets	0	77,000	0	526,000
gain on lease terminations			0	0
unrealized loss on clearpoint equity investments							-1,592,000
unrealized loss on clearpoint convertible debt security			0	0			-1,916,000														-2,050,000	2,799,000
unrealized gain on marketable securities - equity investments	-764,000	-774,000
deferred income taxes		2,000	-55,910,000	-3,000	2,000	-1,000	3,979,000	-2,000	-50,903,000	-4,000
amortization of discounts on investments	-4,556,000	-2,313,000		-2,954,000	-3,296,000	-3,697,000														76,000	-302,000	-333,000		-467,000
amortization of debt issuance costs	302,000	299,000	307,000	300,000	295,000	296,000	299,000	573,000	563,000	438,000	585,000	381,000	471,000	464,000	471,000	466,000	459,000	452,000	254,000	256,000	254,000	256,000	260,000	154,000	141,000	139,000	134,000	134,000	130,000	126,000	125,000	123,000	105,000	80,000	78,000	77,000	75,000	72,000
share-based compensation expense	18,543,000	18,060,000	17,239,000	19,755,000	19,243,000	18,378,000	16,508,000	26,942,000	29,371,000	28,815,000	27,344,000	28,670,000	27,730,000	26,589,000	26,236,000	25,871,000	25,699,000	25,707,000	21,416,000	16,779,000	16,910,000	15,220,000	11,466,000	10,484,000	10,921,000	9,263,000	8,479,000	8,942,000	8,083,000	7,748,000	6,477,000	7,168,000	7,885,000	9,029,000	8,399,000	8,959,000	8,736,000	8,915,000	8,054,000	8,328,000	9,748,000	4,622,000	4,278,000	3,705,000	2,639,697
unrealized foreign currency transaction losses (gains)						269,000									14,111,000	17,297,000								143,000	-803,000	865,000
changes in operating assets and liabilities:
inventory	-10,782,000	2,191,000	11,086,000	-3,106,000	-1,936,000	120,000	5,938,000	-4,326,000	-5,183,000	-4,612,000	-5,900,000	-795,000	-323,000	350,000	-676,000	570,000	-57,000	1,963,000	1,451,000	-553,000	841,000	102,000	-1,882,000	-722,000	-518,000	-334,000	-2,571,000	141,000	-1,947,000	-1,446,000	-2,829,000	-819,000	-1,456,000	-1,350,000
prepaid expenses and other current assets	4,232,000	-16,429,000	-9,194,000	8,166,000	5,887,000	93,904,000	-104,459,000	-4,484,000	6,340,000	57,611,000	-16,006,000	-52,046,000	-8,687,000	25,118,000	-23,471,000	-7,488,000	44,000	15,605,000	-3,332,000	7,280,000	-9,894,000	-6,675,000	2,936,000	-4,521,000	-7,059,000	-191,000	-308,000	-1,555,000	-704,000	958,000	-1,214,000	-154,000	-509,000	93,000	76,000	-68,000	461,000	702,000
trade and royalty receivables	21,901,000	-47,792,000	40,761,000	-7,719,000	8,190,000	-39,500,000	8,348,000	8,135,000	25,404,000	-43,426,000	-23,695,000	4,776,000	-1,177,000	-28,372,000
deposits and other assets	-216,000	-611,000	4,550,000	-2,153,000	-1,130,000	11,192,000	625,000	-2,339,000	6,193,000	743,000	839,000	-2,778,000	-464,000	-510,000	212,000	-155,000	-425,000	136,000	-445,000	-42,000	5,644,000	-5,819,000	-3,176,000	-5,091,000	1,098,000	-10,754,000	-708,000	34,000	-111,000	-308,000	-59,000	-22,000	-237,000	-226,000	-124,000				-75,000	120,000	138,000			17,000	-6,877
accounts payable and accrued expenses	-11,638,000	18,502,000	-32,905,000	18,285,000	-13,313,000	-5,389,000	7,912,000	7,997,000	-1,087,000	33,524,000	25,974,000	10,628,000	21,620,000	-30,680,000	36,771,000	18,111,000	19,533,000	-28,756,000	16,408,000	61,887,000	-3,497,000	-4,000,000	26,141,000	8,241,000	21,107,000	-28,653,000	25,271,000	16,381,000	9,035,000	-6,810,000	12,204,000	-645,000	16,375,000	-3,923,000	2,179,000										147,022
other liabilities	-16,862,000	-458,000	16,563,000	-1,841,000	-8,876,000	5,984,000	-551,000	1,299,000	933,000	-3,988,000	-3,650,000	3,259,000	-1,078,000	-3,089,000	-2,364,000	-1,257,000	-1,167,000	-1,916,000	166,000			1,264,000	1,115,000	3,902,000	586,000	8,065,000	315,000	1,132,000	960,000	-475,000		350,000	1,081,000	-624,000
deferred revenue	-3,355,000	7,200,000	5,718,000	0	0	-801,000	-423,000	1,224,000	-214,000	-1,137,000					45,000	30,000	-1,931,000	-2,154,000	-2,092,000	-2,015,000	-2,725,000	-1,200,000	-2,969,000	-930,000	1,937,000	574,000	581,000	2,729,000	1,795,000	1,409,000	-1,241,000	6,106,000	4,022,000	582,000	758,000	181,000	344,000	243,000
payments on contingent consideration	0	-4,684,000	0
net cash from operating activities	-58,333,000	870,103,000	-30,004,000	-76,992,000	-71,453,000	70,761,000	-100,288,000	-14,519,000	-14,120,000	-29,491,000	-165,963,000	-38,045,000	-55,242,000	-97,404,000	-68,840,000	-51,190,000	-31,145,000	-100,157,000		26,659,000	-74,810,000	-81,554,000	-10,206,000	-15,502,000	-30,522,000	-42,409,000	-15,143,000	3,377,000	3,000	-15,878,000	21,288,000	-15,769,000	13,320,000	-28,902,000	-13,319,000
cash flows from investing activities
purchases of fixed assets	-1,317,000	-1,724,000	-3,767,000	-522,000	7,375,000	-9,588,000	-5,566,000	-6,357,000	-6,245,000	-10,270,000	-8,622,000	-5,382,000	-8,700,000	-9,312,000	-8,726,000	-5,844,000	-7,974,000	-5,669,000	-6,352,000	-3,308,000	-2,160,000	-6,023,000	-4,653,000	-4,253,000	-1,986,000	-2,865,000	-4,608,000	-1,302,000	-708,000	-479,000	-2,043,000	-479,000	-354,000	-225,000	-1,236,000
proceeds from sale of fixed assets	0	70,000	0	18,000
purchases of marketable securities- available for sale	-524,829,000	-322,335,000	-131,304,000	-184,946,000	-187,361,000	-104,373,000					-12,335,000	0	-1,394,000	-39,035,000	-56,772,000	-83,445,000	-50,946,000	-141,985,000
purchases of marketable securities- equity investments	-11,820,000	-5,209,000	-9,763,000	-32,208,000	-8,341,000	-9,065,000	-12,020,000	-8,219,000			0				-4,636,000	-5,382,000	0	-200,000,000
sale and redemption of marketable securities- available for sale	110,401,000	136,750,000	258,773,000	154,186,000	75,000,000	61,650,000	0	0	9,044,000	12,500,000	63,244,000	84,456,000	90,433,000	167,101,000	150,179,000	178,603,000	122,623,000	392,093,000
sale and redemption of marketable securities- equity investments	8,233,000	8,896,000	6,503,000	21,051,000	19,366,000	1,207,000	120,150,000	7,829,000	2,053,000	2,196,000	8,527,000	100,801,000	1,207,000	2,423,000	3,541,000
acquisition of product rights and licenses	-2,677,000	-808,000	-2,730,000	-10,254,000	0	-54,763,000	-22,896,000	-22,849,000	-13,039,000	-33,397,000	-18,375,000	-20,643,000	-9,292,000	-72,134,000	-15,312,000	-19,968,000	-7,646,000	-14,192,000		-23,196,000	9,012,000	-11,434,000		-8,269,000			-1,451,000
net cash from investing activities	-422,009,000	-184,360,000	267,712,000	-42,675,000	-65,923,000	-114,932,000	-94,418,000	-29,596,000	-23,752,000	-28,971,000	32,439,000	136,445,000	72,254,000	49,043,000	68,274,000	64,704,000	56,057,000	30,147,000		-394,211,000	142,057,000	-101,274,000	-228,997,000	30,429,000	-38,171,000	-150,498,000			7,744,000	-1,648,000	-54,042,000	19,272,000	23,469,000	24,418,000	23,131,000	38,236,000	20,997,000	22,117,000
cash flows from financing activities
proceeds from exercise of options	1,134,000	15,751,000	23,245,000	573,000	2,717,000	2,030,000	269,000	3,446,000	14,670,000	5,655,000	1,429,000	10,005,000	754,000	2,444,000	1,189,000	2,976,000	1,389,000	11,755,000	37,192,000	7,942,000	15,058,000	9,987,000	6,081,000	8,066,000	2,848,000	1,281,000	2,237,000	5,039,000	2,456,000	1,136,000	745,000	902,000	429,000	106,000	42,000	892,000	0	34,000	617,000	5,053,000	3,019,000	359,000
proceeds from employee stock purchase plan			3,226,000	0			2,149,000	0			3,343,000	0			3,165,000	0				0
proceeds from sale of future royalties
payments on contingent consideration obligation	0	-6,341,000
payment of finance lease principal			0	0	0	-1,490,000	0	0	0	-1,379,000	0	0	0	-1,276,000	0	0	0	-2,224,000		-2,829,000
net cash from financing activities	3,961,000	9,410,000	26,471,000	-17,627,000	246,482,000	540,000	620,485,000	3,361,000	18,460,000	4,094,000	302,918,000	-139,995,000	3,861,000	1,168,000	4,354,000	2,976,000	4,016,000	9,531,000	40,089,000	643,054,000	-32,918,000	18,490,000	2,284,000	382,354,000	2,849,000	225,722,000	3,726,000	5,080,000	121,629,000	1,136,000	1,851,000	1,707,000	39,997,000	663,000	42,000	892,000	0	34,000	145,967,000	5,053,000	3,019,000	359,000	218,000	118,146,000	-2,856,428
effect of exchange rate changes on cash	13,588,000	5,393,000	-8,653,000	8,542,000	-5,187,000	-2,030,000	3,095,000	-2,332,000	10,314,000	-7,963,000	6,020,000	-12,139,000	1,694,000	1,653,000	-3,888,000	-4,019,000	1,787,000	-1,701,000	7,239,000	7,000	845,000	-403,000	1,370,000	-2,298,000	794,000	-1,169,000	-1,402,000	-1,219,000	-3,263,000	2,273,000	857,000	3,617,000	2,119,000	-394,000	-1,819,000	-425,000	-919,000	1,579,000
net increase in cash and cash equivalents	-462,793,000	700,546,000																				-164,741,000	-235,549,000	394,983,000	-65,050,000	31,646,000	-37,415,000	-16,875,000			-30,046,000	8,827,000			8,035,000							31,701,000	-94,683,000	100,441,000	-130,050,450
cash and cash equivalents, and restricted cash beginning of period	0	795,316,000	0	0	0	610,284,000	0	0	0	295,925,000	0	0	0	197,218,000	0	0	0	216,312,000	0	0	0	295,528,000
cash and cash equivalents, and restricted cash end of period	-462,793,000	1,495,862,000	255,526,000	-128,752,000	103,919,000	564,623,000	428,874,000	-43,086,000	-9,098,000	233,594,000	175,414,000	-53,734,000	22,567,000	151,678,000	-100,000	12,471,000	30,715,000	154,132,000	-225,158,000	275,509,000	35,174,000	130,787,000	-235,549,000
supplemental disclosure of cash information
cash paid for interest	0	2,156,000	0	2,157,000	0	3,666,000		11,710,000	9,354,000	12,956,000		4,406,000	2,143,000	6,130,000	-1,000	4,407,000	0	5,182,000				4,878,000		3,931,000	0	3,111,000	846,000	3,089,000	815,000	3,023,000	775,000	3,022,000	224,000	2,250,000	0	2,250,000	0	2,263,000				0	0	1,000	83,115
cash paid for income taxes	36,148,000	3,040,000	4,769,000	6,664,000	4,075,000	2,042,000		4,435,000	6,981,000	2,215,000		1,080,000	962,000	1,987,000	2,181,000	1,400,000	3,440,000	687,000				507,000		918,000	476,000	537,000	664,000	161,000	432,000	326,000	485,000	282,000	306,000	28,000	310,000	369,000	39,000	225,000
supplemental disclosure of non-cash investing and financing activity
unrealized loss on marketable securities, net of tax	-186,000	-88,000										736,000	-156,000	-2,913,000				-1,294,000
right-of-use assets obtained in exchange for operating lease obligations	0	850,000	676,000	4,063,000	0	1,723,000						-33,348,000	68,055,000	587,000			0	13,000
fixed asset additions through tenant improvement allowance	11,000	374,000	173,000	1,936,000
milestone payable			-38,975,000	12,500,000	35,000,000	2,500,000		0	-30,000,000	32,500,000		0
unrealized gain on clearpoint equity investments		3,122,000							1,073,000	39,000	2,447,000	3,482,000	-3,418,000	1,049,000	8,454,000
unrealized gain on clearpoint convertible debt security						-166,000					3,348,000	4,387,000	-3,537,000	1,542,000	10,335,000
disposal of asset			269,000			544,000	671,000	2,000						79,000
unrealized foreign currency transaction losses		2,251,000										34,887,000	34,224,000	2,135,000								8,675,000											828,000	820,000	-199,000	438,000
intangible asset impairment							0	0
gain on lease modification
gain on sale of priority review voucher
unrealized (gain) loss on clearpoint equity investments			-3,731,000			-9,000											2,654,000	-6,764,000
realized loss for the sale of clearpoint equity investment
realized loss on clearpoint convertible debt security			0
realized gain on redemption of marketable securities - equity investments
unrealized (gain) loss on marketable securities - equity investments
non-cash stock consideration, milestone payment							0	0
amortization of (discounts) premiums on investments							-2,111,000	-1,000	-3,000	-85,000																-257,000
loss on extinguishment of debt
unrealized foreign currency transaction (gains) losses									-3,275,000	-10,057,000										-23,829,000									536,000	-1,300,000	-95,000
non-cash foreign currency remeasurement loss on intercompany loan
proceeds from sale of priority review voucher
sale and redemption of clearpoint equity investments							0	0
proceeds from settlement of clearpoint convertible debt security
repayment of senior secured term loan																			0	-18,333,000	-5,000,000	-5,000,000	-5,000,000	-5,000,000
debt extinguishment costs related to senior secured term loan
cash consideration received from a&r royalty purchase agreement
debt issuance costs related to senior secured term loan							0	-85,000	-15,000	-182,000
proceeds from issuance of senior secured term loan
repayment of convertible notes											0
proceeds from stock purchase agreement
unrealized gain on marketable securities, net of tax			-2,261,000	2,760,000	-112,000	-444,000		19,000	397,000	54,000						-136,000						-63,000
accrued brokerage fees in connection with sale of priority review voucher
capital expenditures unpaid at the end of the period
unrealized gain on marketable securities- equity investments				-812,000	-401,000	-710,000					-3,327,000	-37,000			-323,000	-656,000
proceeds from principal payment of clearpoint convertible debt security
proceeds from sales of future royalties				0
debt issuance costs related to secured loan
net decrease in cash and cash equivalents						-45,661,000		-43,086,000	-9,098,000	-62,331,000		-53,734,000	22,567,000	-45,540,000	-100,000	12,471,000	30,715,000	-62,180,000	-225,158,000	275,509,000										-14,117,000				-4,215,000
unrealized foreign currency transaction gains																		24,691,000
realized gain on redemption of marketable securities- equity investments
unrealized (gain) loss on marketable securities- equity investments							2,967,000	-1,120,000	-2,198,000	-2,166,000
purchase of equity investment in clearpoint															0	0	0	-100,000
payments on deferred and contingent consideration obligation
realized loss on the sale of clearpoint equity investment
capital expenditures unpaid at the end of period									8,000	28,000
change in valuation of deferred and contingent consideration										2,400,000	6,300,000	-5,300,000	-15,200,000	-11,700,000	-12,100,000	10,800,000	700,000	100,000	6,300,000	8,400,000	7,680,000	900,000		9,500,000	5,300,000	21,160,000
unrealized (gain) loss on clearpoint convertible debt security										-59,000							3,532,000	-7,858,000
non-cash finance lease amortization expense																				170,000
settlement of deferred and contingent consideration																				0
non-cash stock consideration, acquisition																				0
amortization of premiums on investments											-79,000	252,000	653,000	887,000																-96,000	42,000	128,000	157,000	208,000	275,000	470,000	509,000	631,000	404,000	429,000	486,000	315,000	496,000	414,000
non-cash interest expense																			5,920,000	5,685,000	5,534,000	5,459,000	5,444,000	2,528,000	2,073,000	1,982,000	1,955,000	1,919,000	1,864,000	1,780,000	1,756,000	1,725,000	1,674,000	1,600,000	1,578,000	1,546,000	1,495,000	1,446,000
purchase of convertible debt security																				0	0	-10,000,000
termination and exit fees related to payoff of senior secured term loan
net proceeds from public offerings																			0	9,142,000	5,447,000	13,503,000		99,717,000	104,000	224,441,000		41,000														0
cash consideration received from royalty purchase agreement
loss on disposal of asset												-1,000								-1,000												-42,000
unrealized loss on marketable securities- equity investments														6,477,000				302,000
amortization of premiums (discounts) on investments															1,247,000	1,408,000	1,285,000	1,359,000
proceeds from issuance of convertible notes																							-304,000
termination and exit fees related to payoff of secured term loan																			0
payments on deferred consideration obligation																				-2,271,000
trade receivables																-19,205,000	15,590,000	-25,010,000	-10,604,000	-1,739,000	-486,000	2,346,000	5,646,000	15,581,000	-30,488,000	20,786,000	-26,908,000	17,748,000	-16,206,000	-4,223,000	-1,209,000	-4,232,000	-16,000	-6,746,000	1,193,000
right-of-use assets obtained in exchange for finance lease obligations
issuance of common stock related to rights exchange
unrealized gain on equity investment in clearpoint
purchases of marketable securities																				-639,844,000	-68,288,000	-298,814,000	-254,682,000	-13,125,000	-60,538,000	-165,723,000	-39,958,000	0	-5,973,000	-22,683,000	-61,901,000	0	0	-19,467,000	-11,685,000
sale and redemption of marketable securities																				272,137,000	203,493,000	224,997,000		56,076,000	40,334,000	18,090,000		29,984,000	14,425,000	21,514,000		20,490,000	100,247,000	44,110,000		65,937,000
purchase of equity investment
business acquisition, net of cash acquired																											0
unrealized gain on equity investment
unrealized loss on equity investment
other long-term liabilities																																			-1,481,000	681,000
non-cash lease expense																						1,330,000
unrealized loss on equity investment in clearpoint																						1,574,000
right-of-use assets obtained in exchange for lease obligations																						22,642,000			329,000	11,314,000
change in the fair value of deferred and contingent consideration
sale & redemption of marketable securities																																						41,795,000			40,598,000
acquisition of product rights																											-4,530,000
proceeds from shares issued under employee stock purchase plan																							2,013,000	0			1,488,000	0			1,106,000	805,000	0	557,000
debt issuance costs related to secured term loan																															0	0
net proceeds from public offering
proceeds from issuance of secured term loan																															0	0
cash and cash equivalents, beginning of period																									0	169,498,000	0	0	0	111,792,000	0	0	0	58,321,000	0	0	0	58,022,000	0	0	49,748,000	0	0	15,414,000	0
change in valuation of warrant liability																																0			-91,000	-3,000					41,000	40,000	-17,000	55,000
unrealized gain on mri investment																								-2,400,000
purchases of equity investment in mri																								0
change in unrealized gain on marketable securities, net of tax																								-463,000	839,000	59,000	59,000						-9,000	-22,000		-189,000
cash and cash equivalents, end of period																									-65,050,000	201,144,000	-37,415,000	-16,875,000	126,113,000	97,675,000	-30,046,000	8,827,000	78,905,000	54,106,000	8,035,000	14,628,000	-4,507,000	40,165,000	111,492,000	-7,605,000	36,825,000	31,701,000	-94,683,000	115,855,000	-130,050,450
benefit for deferred income taxes																																			23,000
supplemental disclosures of non-cash information related to investing and financing activities
amortization of premiums and accretion of discounts on investments																												-124,000
net cash (used in) / provided by investing activities
acquisition, including transaction costs																															0	-739,000
debt issuance costs related to convertible notes
change in unrealized gain on marketable securities																																						658,000		-224,000	125,000		10,000	10,000
depreciation																																		612,000	813,000	813,000	815,000	849,000	760,000	685,000	634,000	543,000	562,000	588,000	588,556
payments on long-term debt
receivables																																									1,267,000
sales & redemptions of marketable securities
net cash provided by/(used in) investing activities																																							-6,284,000
change in unrealized loss on marketable securities																																													-39,695
net (decrease)/increase in cash and cash equivalents
net cash provided/(used in) investing activities																																									20,607,000
net increase/(decrease) in cash and cash equivalents
grant and collaboration receivables																																											-20,000	120,000	86,790
net proceeds from sale of series four convertible preferred stock																																													0
change in carry value of preferred securities resulting from recapitalization																																													0
maturities of marketable securities																																											31,806,000	21,273,000	6,487,191
ipo closing costs included in accounts payable and accrued expenses
net proceeds from secondary offering																																												118,183,000
net proceeds from sale of series one convertible preferred stock
net proceeds from initial public offering																																													-70,629
noncash interest expense
supplemental disclosures of noncash information related to investing and financing activities

We provide you with 20 years of cash flow statements for PTC Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PTC Therapeutics stock. Explore the full financial landscape of PTC Therapeutics stock with our expertly curated income statements.

The information provided in this report about PTC Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.